Amifru S Tablet (10 Tab)

About Amifru S Tablet:

Amifru S Tablet is a combination medication, indicated for edema-associated conditions and the treatment of mild and moderate degrees of essential hypertension.

Each film-coated Amifru S Tablet contains Furosemide 20 mg and Spironolactone 50 mg.

Furosemide and Spironolactone both are diuretics and come under the antihypertensive class of medication.

Furosemide belongs to a class of loop diuretic medicines. It acts by increasing the production of more urine to excrete excess fluid and certain electrolytes from the body.  

Spironolactone belongs to a class of potassium-sparing diuretics and acts as an aldosterone antagonist. It inhibits the action of the hormone aldosterone, thereby, elevating the excretion of salt and water through urine while preventing potassium loss in the body.

Use of Amifru S Tablet:

Amifru S Tablet is prescribed for edema in conditions where potassium ion conservation is important that is:

• Congestive cardiac failure
• Nephrotic syndrome (kidney disorder)
• Ascites associated with liver cirrhosis.

It is also prescribed for the treatment of mild and moderate degrees of essential hypertension (high blood pressure).

Usage Direction of Amifru S Tablet:

• Amifru S Tablet is intended for oral use only, in a dose and direction as prescribed by the physician.
• Amifru S Tablet is taken whole with the help of water.
• Do not crush, chew or break the tablet.
• Do not skip or stop the medicine without the physician’s advice.
• Do not consume more than the prescribed quantity.

Precaution & Related information of Amifru S Tablet:

• If hypersensitive or allergic to Amifru S Tablet, inform the physician immediately.
• In patients with hepatic cirrhosis and ascites (abnormal accumulation of fluid in the abdomen), furosemide therapy is best initiated in the hospital.
• In hepatic coma and states of electrolyte depletion, therapy should not be instituted until the basic condition is improved.
• Sudden alterations of fluid and electrolyte balance in patients with cirrhosis may precipitate hepatic coma, therefore, strict observation is necessary during the period of diuresis.
• If increasing azotemia and oliguria occur during treatment of severe progressive renal (kidney) disease, furosemide should be discontinued.
• Urine and blood glucose should be checked periodically in diabetics receiving furosemide.
• Furosemide may lower serum levels of calcium (rarely cases of tetany have been reported) and magnesium. Accordingly, serum levels of these electrolytes should be determined periodically.
• Inform the physician, that in case of tinnitus and reversible or irreversible hearing impairment and deafness have been reported.
• Potassium supplementation, either in the form of medication or as a diet rich in potassium, should not ordinarily be given in association with spironolactone therapy.
• Spironolactone should be used with caution in patients with severe heart failure.
• Spironolactone therapy may cause a transient elevation of BUN (blood urea nitrogen), especially in patients with pre-existing renal impairment.
• Somnolence and dizziness have been reported to occur in some patients. Caution is advised when driving or operating machinery until the response to initial treatment has been determined.  
• If found any other complications, inform the physician immediately.
• The Physician should be well informed when concomitant consumption of this tablet with any other medicines or supplements.
• Consult with the physician during pregnancy & lactation.
• Keep out of reach of children.

Storage condition of Amifru S Tablet:

Store in a cool, dry place. Protect from light.